In February 2020, University of Pittsburgh professor José-Alain Sahel received an encouraging phone call. A research subject in Paris who was receiving an experimental treatment for blindness developed by Dr. Sahel was reporting the ability to see lines on a crosswalk. Prior to the treatment, he could only distinguish light from dark.
“It was like 15 years of work all of a sudden made sense,” said Dr. Sahel. “I was very excited.”
But … it was February of 2020. Ten days later, COVID-19 shut the world down, including the ability to do in-person research in France.
Without the ability to confirm the results, Dr. Sahel didn’t breathe a word about his possible breakthrough. When France began allowing research again over the summer of 2020, his team was able to test and confirm results.
In May 2021, Dr. Sahel and his team published their findings in the journal Nature Medicine, documenting the first time that optogenetic therapy was used to partially restore vision in a patient affected by genetic blindness.
Now, he is expanding his research to test the therapy on people in Pittsburgh also afflicted with retinitis pigmentosa, the most common cause of genetic blindness in young adults.
Read More
The field of optogenetics uses a protein derived from algae to make neurons in the brain sensitive to light. Scientists can then use light to turn those neurons on and off, helping to map the brain.
To apply the field to blindness, Dr. Sahel and his colleagues thought they might be able to use optogenetics to increase light sensitivity in cells in the retina.
Now 58, the subject in France had been diagnosed with retinitis pigmentosa as a teenager and gradually lost his sight. For the past 15 years, he had no vision at all, other than some light sensitivity.
“The last time he could see his own hair it was black, and now it is white,” Dr. Sahel said.
Dr. Sahel and his team injected the patient’s worse-seeing eye with a virus carrying a protein that would make it sensitive to amber light. They also developed special goggles implanted with a camera that constantly scans the field of vision and transmits amber light into the eye based on what the camera sees.
“This is not natural vision,” Dr. Sahel said. “This is a new type of vision that is being restored. You need a patient who is strongly motivated.”
The process is slow. It takes several months for the protein injected into the eye to transform the cells, Dr. Sahel said, and then the patient must be trained to use the goggles and adapt to them.
It was nearly a year from the time the patient was injected with the virus until he was able to distinguish the lines of the crosswalk, he said.
In testing done to validate the study, the patient was able to perceive and count whether there were two or three cups placed on the table in front of him in 63% of his attempts. He was also able to perceive and touch a notebook on the table in 92% of his tries.
The subject has given Dr. Sahel feedback on the goggles, and the team has continued to refine and improve them.
He now has what Dr. Sahel describes as “not perfect vision, but useful vision.” The subject is now able to do some cooking, a favorite hobby. “He thought his eyes were dead and would never work again. He’s happy that his eyes are alive.”
In Pittsburgh, two blind subjects began the experiment this summer when they were injected with the virus carrying the protein that will make cells in their retinas more sensitive to amber light.
The protein generally takes several months to begin expressing itself in the retina, and during that time, the patients will begin their training on the goggles. It is possible that this spring — nine months after injection — they might start seeing results.
“It will take a while before we know how it works. It may not work with everyone,” said Dr. Sahel. “What we know is that the brain is learning, and the brain is a very adaptive organ. We are improving the goggles, working on the goggles. It will never go back to normal vision, but there is some improvement that can happen.”
Anya Sostek: asostek@post-gazette.com.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.